ECP-105
Glaucoma (adjunct to Bleb surgery)
Pre-clinicalActive
Key Facts
About Nanogenics
NanoGenics is a private, pre-revenue biotechnology company leveraging its proprietary LipTide delivery technology to advance RNA-based therapeutics. The platform is designed to overcome key delivery challenges in gene therapy, offering targeted cell delivery, low toxicity, and repeat dosing potential. The company's most advanced candidate, ECP-105, targets glaucoma, representing a near-term clinical opportunity, while the platform's broad applicability provides long-term value across multiple therapeutic areas. Leadership appears lean, with a General Manager cited, suggesting a focused operational structure.
View full company profile